-
公开(公告)号：US5684016A
公开(公告)日：1997-11-04
申请号：US445543
申请日：1995-05-22
IPC分类号： A61K38/00 , A61K38/55 , C07K5/02 , A61K31/47 , C07D217/26
CPC分类号： C07K5/0222 , A61K38/556
摘要： The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 and R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.
摘要翻译： 本发明涉及通过使用其中n为1或2的式I（I）的化合物治疗心功能不全的方法，R 1，R 2，R 2和R 3相同或不同，并且各自表示氢或有机基团 并且R4和R5与携带它们的原子一起形成单环，双环或三环杂环体系。 本发明还涉及式I化合物和含有这些化合物用于治疗上述疾病的药剂。
-
2.发明授权Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors 失效使用血管紧张素转换酶抑制剂治疗心功能不全的方法
公开(公告)号：US5403856A
公开(公告)日：1995-04-04
申请号：US188745
申请日：1994-01-31
IPC分类号： C07K14/81 , A61K38/00 , A61K38/55 , A61P9/00 , A61P9/12 , A61P43/00 , C07K5/02 , C07K5/06 , C12N9/99 , A61K31/40
CPC分类号： A61K38/556 , C07K5/0222 , Y10S514/913
摘要： The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.
摘要翻译： 本发明涉及通过使用其中n为1或2的式I（I）的化合物治疗心功能不全的方法，R 1，R 2，R 2和R 3相同或不同，并且各自表示氢或有机基团 和R4 R5与携带它们的原子一起形成单环，双环或三环杂环体系。 本发明还涉及式I化合物和含有这些化合物用于治疗上述疾病的药剂。
-
公开(公告)号：US5158959A
公开(公告)日：1992-10-27
申请号：US565900
申请日：1983-12-27
IPC分类号： A61K38/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/47 , A61K31/472 , A61P9/12 , C07D209/42 , C07D217/26 , C07D233/64 , C07D241/20 , C07D307/54 , C07D309/10 , C07D317/66 , C07D333/24 , C07D335/02 , C07D339/08 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07K1/02 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/062 , C07K5/065 , C07K5/078 , C07K14/81
CPC分类号： C07K5/0222 , C07D217/26 , A61K38/00
摘要： What are disclosed are aminoacid compounds of the formula ##STR1## wherein n is 0 or 1, and salts thereof, said compounds and salts having hypotensive properties; methods for making the compounds; pharmaceutical compositions containing the compounds or salts; and use of the compounds and salts for treating hypertension.
摘要翻译： 所公开的是下式的氨基酸化合物，其中n为0或1，及其盐，所述化合物和具有降血压性质的盐; 制备化合物的方法; 含有该化合物或盐的药物组合物; 以及使用化合物和盐治疗高血压。
-
公开(公告)号：US5747504A
公开(公告)日：1998-05-05
申请号：US709286
申请日：1996-09-06
CPC分类号： C07K5/0222 , A61K38/556
摘要： The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 and R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.
-
5.发明授权Aminoacid derivatives, a process for their preparation, agents containing these compounds, and the use thereof 失效氨基酸衍生物，其制备方法，含有这些化合物的试剂及其用途
公开(公告)号：US5401766A
公开(公告)日：1995-03-28
申请号：US208443
申请日：1994-03-09
IPC分类号： A61K38/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/47 , A61K31/472 , A61P9/12 , C07D209/42 , C07D217/26 , C07D233/64 , C07D241/20 , C07D307/54 , C07D309/10 , C07D317/66 , C07D333/24 , C07D335/02 , C07D339/08 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07K1/02 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/062 , C07K5/065 , C07K5/078 , C07K14/81 , C07D209/34 , A61K31/405
CPC分类号： C07K5/0222 , C07D217/26 , A61K38/00
摘要： Aminoacid derivatives of the formula I ##STR1## A , n, R.sup.1, R.sup.2 and R.sup.3 have the meanings given, and salts thereof, a process for their preparation, pharmaceutical preparations based on these compounds, and their use as medicaments.
摘要翻译： 式I的氨基酸衍生物A，n，R 1，R 2和R 3具有给定的含义及其盐，其制备方法，基于这些化合物的药物制剂及其作为药物的用途。
-
公开(公告)号：US5162362A
公开(公告)日：1992-11-10
申请号：US565887
申请日：1983-12-27
IPC分类号： A61K38/00 , C07D217/26 , C07K5/02
CPC分类号： C07K5/0222 , C07D217/26 , A61K38/00
摘要： What are disclosed are aminoacid compounds of the formula ##STR1## wherein n is 0 or 1, and salts thereof, said compounds and salts having hypotensive properties; methods for making the compounds; pharmaceutical compositions containing the compounds or salts; and use of the compounds and salts for treating hypertension.
摘要翻译： 所公开的是下式的氨基酸化合物，其中n为0或1，及其盐，所述化合物和具有降血压性质的盐; 制备化合物的方法; 含有该化合物或盐的药物组合物; 以及使用化合物和盐治疗高血压。
-
公开(公告)号：US4624962A
公开(公告)日：1986-11-25
申请号：US697340
申请日：1985-02-01
IPC分类号： C07C275/16 , C07C67/00 , C07C239/00 , C07C275/24 , C07C279/14 , C07C301/00 , C07C303/40 , C07C311/30 , C07C313/00 , C07C315/04 , C07C317/50 , C07C323/44 , C07C323/57 , C07C323/59 , C07D207/16 , C07D207/22 , C07D209/20 , C07D209/42 , C07D209/52 , C07D211/60 , C07D213/55 , C07D217/12 , C07D217/26 , C07D223/06 , C07D231/12 , C07D233/54 , C07D277/06 , C07D333/24 , C07D333/60 , C07D401/12 , C07D403/12 , C07D409/12 , C07D471/04 , C07D495/04 , A61K31/40
CPC分类号： C07D231/12 , C07C275/24 , C07C323/44 , C07D207/16 , C07D207/22 , C07D209/20 , C07D209/42 , C07D209/52 , C07D211/60 , C07D213/55 , C07D217/26 , C07D223/06 , C07D233/64 , C07D277/06 , C07D333/24 , C07D333/60 , C07D401/12 , C07D403/12 , C07D409/12 , C07D471/04 , C07D495/04 , C07C2101/04 , C07C2101/08
摘要： Compounds of the formula I ##STR1## in which n denotes 0-3,R.sup.1 and R.sup.1' are the same or different and denote hydrogen, alkyl or alkenyl, phenyl or benzyl, each substituted as desired;R.sup.2 denotes hydrogen, alkyl or alkenyl;R.sup.3 denotes hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl or aminoalkyl, alkanoylaminoalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl, mercaptoalkyl or alkylthioalkyl, phenylalkyl, hydroxphenylalkyl, phenoxyalkyl or phenylthioalkyl, or R.sup.2 and R.sup.3, together with the C and N atoms carrying them, denote a saturated or unsaturated 4- to 8-membered monocyclic or 8- to 10-membered bicyclic isocycle or heterocycle, optionally monosubstituted or disubstituted by hydroxyl, alkoxy having 1 to 3 C atoms or alkyl,R.sup.4 denotes hydrogen, alkyl, alkenyl, alkadienyl, alkinyl, alkeninyl or alkadiinyl, cycloalkyl, phenyl, benzyl, phenethyl or phenylpropyl, each of which can be optionally monosubstituted or disubstituted;R.sup.5 denotes hydrogen or alkyl, hydroxyl or alkoxy andR.sup.6 denotes hydrogen, optionally substituted alkyl, cycloalkyl, alkenyl, optionally monosubstituted or disubstituted phenyl or naphthyl, their salts, a process for their preparation and their use as medicaments.
摘要翻译： 式I的化合物其中n表示0-3，R1和R1'相同或不同，表示氢，烷基或链烯基，苯基或苄基，各自根据需要取代; R2表示氢，烷基或烯基; R3表示氢，烷基，羟基烷基，烷氧基烷基或氨基烷基，烷酰基氨基烷基，胍基烷基，咪唑基烷基，吲哚基烷基，巯基烷基或烷硫基烷基，苯基烷基，羟基苯基烷基，苯氧基烷基或苯硫基烷基，或R2和R3与携带它们的C和N原子一起表示饱和 或不饱和的4至8元单环或8至10元双环的单环或杂环，任选被羟基，具有1至3个C原子的烷氧基或烷基单取代或二取代，R4表示氢，烷基，烯基，链烯基，炔基， 链烯基或烷撑基，环烷基，苯基，苄基，苯乙基或苯基丙基，它们各自可以任选被单取代或二取代; R5表示氢或烷基，羟基或烷氧基，R6表示氢，任选取代的烷基，环烷基，烯基，任选单取代或二取代的苯基或萘基，它们的盐，其制备方法及其作为药物的用途。
-
公开(公告)号：US4515803A
公开(公告)日：1985-05-07
申请号：US413663
申请日：1982-09-01
IPC分类号： C07C275/16 , C07C67/00 , C07C239/00 , C07C275/24 , C07C279/14 , C07C301/00 , C07C303/40 , C07C311/30 , C07C313/00 , C07C315/04 , C07C317/50 , C07C323/44 , C07C323/57 , C07C323/59 , C07D207/16 , C07D207/22 , C07D209/20 , C07D209/42 , C07D209/52 , C07D211/60 , C07D213/55 , C07D217/12 , C07D217/26 , C07D223/06 , C07D231/12 , C07D233/54 , C07D277/06 , C07D333/24 , C07D333/60 , C07D401/12 , C07D403/12 , C07D409/12 , C07D471/04 , C07D495/04 , C07D209/12
CPC分类号： C07D231/12 , C07C275/24 , C07C323/44 , C07D207/16 , C07D207/22 , C07D209/20 , C07D209/42 , C07D209/52 , C07D211/60 , C07D213/55 , C07D217/26 , C07D223/06 , C07D233/64 , C07D277/06 , C07D333/24 , C07D333/60 , C07D401/12 , C07D403/12 , C07D409/12 , C07D471/04 , C07D495/04 , C07C2101/04 , C07C2101/08
摘要： Compounds of the formula I ##STR1## in which n denotes 0-3,R.sup.1 and R.sup.1' are the same or different and denote hydrogen, alkyl or alkenyl, phenyl or benzyl, each substituted as desired;R.sup.2 denotes hydrogen, alkyl or alkenyl;R.sup.3 denotes hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl or aminoalkyl, alkanoylaminoalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl, mercaptoalkyl or alkylthioalkyl, phenylalkyl, hydroxyphenylalkyl, phenoxyalkyl or phenylthioalkyl, or R.sup.2 and R.sup.3, together with the C and N atoms carrying them, denote a saturated or unsaturated 4- to 8-membered monocyclic or 8- to 10-membered bicyclic isocycle or heterocycle, optionally monosubstituted or disubstituted by hydroxyl, alkoxy having 1 to 3 C atoms or alkyl,R.sup.4 denotes hydrogen, alkyl, alkenyl, alkadienyl, alkinyl, alkeninyl or alkadiinyl, cycloalkyl, phenyl, benzyl, phenethyl or phenylpropyl, each of which can be optionally monosubstituted or disubstituted;R.sup.5 denotes hydrogen or alkyl, hydroxyl or alkoxy andR.sup.6 denotes hydrogen, optionally substituted alkyl, cycloalkyl, alkenyl, optionally monosubstituted or disubstituted phenyl or naphthyl,their salts, a process for their preparation and their use as medicaments.
摘要翻译： 式I的化合物其中n表示0-3，R1和R1'相同或不同，表示氢，烷基或链烯基，苯基或苄基，各自根据需要取代; R2表示氢，烷基或烯基; R3表示氢，烷基，羟基烷基，烷氧基烷基或氨基烷基，烷酰基氨基烷基，胍基烷基，咪唑基烷基，吲哚基烷基，巯基烷基或烷硫基烷基，苯基烷基，羟基苯基烷基，苯氧基烷基或苯硫基烷基，或R2和R3与携带它们的C和N原子一起表示饱和 或不饱和的4至8元单环或8至10元双环的单环或杂环，任选被羟基，具有1至3个C原子的烷氧基或烷基单取代或二取代，R4表示氢，烷基，烯基，链烯基，炔基， 链烯基或烷撑基，环烷基，苯基，苄基，苯乙基或苯基丙基，它们各自可以任选被单取代或二取代; R5表示氢或烷基，羟基或烷氧基，R6表示氢，任选取代的烷基，环烷基，烯基，任选单取代或二取代的苯基或萘基，它们的盐，其制备方法及其作为药物的用途。
-
9.发明授权Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors 失效使用血管紧张素转换酶抑制剂治疗心功能不全的方法
公开(公告)号：US5744496A
公开(公告)日：1998-04-28
申请号：US359860
申请日：1994-12-20
IPC分类号： C07K14/81 , A61K38/00 , A61K38/55 , A61P9/00 , A61P9/12 , A61P43/00 , C07K5/02 , C07K5/06 , C12N9/99 , A61K31/40
CPC分类号： A61K38/556 , C07K5/0222 , Y10S514/913
摘要： The invention relates to a method of treating cardiac insufficiency by using compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each denote hydrogen or an organic radical and R.sup.4 and R.sup.5, together with the atoms carrying them, form a mono-, bi- or tri-cyclic heterocyclic ring system. The invention furthermore relates to compounds of the formula I and agents containing these for use in the treatment of the abovementioned disease.
摘要翻译： 本发明涉及通过使用其中n为1或2的式I（I）的化合物治疗心功能不全的方法，R 1，R 2，R 2和R 3相同或不同，并且各自表示氢或有机基团 并且R4和R5与携带它们的原子一起形成单环，双环或三环杂环体系。 本发明还涉及式I化合物和含有这些化合物用于治疗上述疾病的药剂。
-
10.发明授权Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia 失效治疗心脏病和血管性高血压和高血压的方法
公开(公告)号：US5231083A
公开(公告)日：1993-07-27
申请号：US564618
申请日：1990-08-09
申请人： Wolfgang Linz , Bernward Scholkens , Wolfgang Scholz , Gabriele Wiemer , Hansjorg Urbach , Rainer Henning , Volker Teetz
发明人： Wolfgang Linz , Bernward Scholkens , Wolfgang Scholz , Gabriele Wiemer , Hansjorg Urbach , Rainer Henning , Volker Teetz
CPC分类号： A61K38/556
摘要： The invention relates to a method for the treatment of cardiac and of vascular hypertrophy and hyperplasia by administration of angiotensin converting enzyme inhibitors. Administration of compounds of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 are identical or different and each is hydrogen or an organic radical, and R.sup.4 and R.sup.5 form, together with the atoms carrying them, a mono-, bi- or tricyclic heterocyclic ring system, is preferred. The invention additionally relates to angiotensin converting enzyme inhibitors and to agents containing these for administration for the treatment of the abovementioned diseases.
摘要翻译： 本发明涉及通过施用血管紧张素转换酶抑制剂治疗心脏和血管肥大和增生的方法。 给予其中n为1或2，R 1，R 2和R 3的式I化合物（I）相同或不同，各自为氢或有机基团，并且R 4和R 5与 携带它们的原子，单环，双环或三环杂环体系是优选的。 本发明还涉及血管紧张素转换酶抑制剂和含有这些用于治疗上述疾病的药剂。
-
-
-
-
-
-
-
-
-
搜索结果
86 条记录 (耗时 0.029 秒)
